180 likes | 399 Views
Atrial Fibrillation In Diabetics : A Turning Point In Life Expectancy. The Electrical System Of The Sweet Heart. G.L. Botto, MD, FACC, FESC U.O. Cardiologia U.O.Elettrofisiologia Ospedale Sant’Anna, Como. Remodeling. Ventricular dilation. MI. HF.
E N D
AtrialFibrillation In Diabetics: A Turning Point In Life Expectancy The Electrical System Of The Sweet Heart G.L. Botto, MD, FACC, FESC U.O. Cardiologia U.O.Elettrofisiologia Ospedale Sant’Anna, Como
Remodeling Ventricular dilation MI HF End-stage microvascular heart disease Atherosclerosis and LVH Risk factors (diabetes, hypertension) Death Atrial fibrillation AFIB Within The Cardiovascular Continuum AF is NOT a DISEASE, but rather a manifestation of a number of CLINICAL SYNDROMES, some of which are curable
CHS Multivariate Correlates of AF Prevalence Age (per 7-yr interval) * 1.03 (1.00–1.05) Gender(men vs women) 1.02 (0.77–1.35) 2.67 (1.57–4.55) CHF * Valvular heart disease * 3.27 (2.23–4.81) 1.57 (0.95–2.60) Stroke * 4.35 (1.42–13.35) Mitral stenosis * 1.62 (1.15–2.29) Aortic regurgitation * 2.69 (2.21–3.27) LA diameter * 1.39 (1.05–1.83) Hypertension * 0 4 8 12 16 * p < 0.05 ( ) 95% CI FurbergCD. Am J Cardiol 1994; 74: 236-241.
Development of a Risk Score for AF: A Community-BasedCohort (Framingham HS)HazardRegressionCoefficient for 10-Year Risk of AF Schnabel RB. Lancet 2009; 373: 739-45
Cumulative Exposure to DM and Risk of Prevalent AFA Casual Association ? Risk of newly AF by duration of treated DM Risk of newly AF by level of Hb A1c Dublin S. J GenInternMed 2010; 25: 853-8
Type 2 Diabetes Mellitus and Riskof Incident AF in Women the risk associated with T2DM is mainly mediated by changes of other AF RF Schoen T. J AmCollCardiol 2012; 60: 1421–8
Type-2 DiabetesMellitus and Risk of AFMeta-Analysis of Cohort and Case-Control Studies on 108.703 Cases • Studiesthathadadjustedfor multiple risk factors reported a smaller effect estimate compared to age-adjusted studies.(RR 1.24, 95% CI 1.06 to 1.44, vs1.70, 1.29 to 2.22). • The population attributable fraction of AF owing to T2DM was 2.5% (95% CI 0.1 to 3.9). Huxley RR. Am J Cardiol 2011; 108: 56-62
How IncreasedGlucoseLevels and DM MayExert a ProarrhythmicEffect ? • No evidence to indicate that T1DM isassociated with an increasedrisk of AF • Collier A. PostgradMed J 1987; 63: 895-897 • Insulinresistenceratherthanhyperglicemiaisresponsible for the increasedrisk of AF • Insulinresistenceisalso a mechanism by whichhypertension and obesityare associated with increasedrisk of AF • Yamagishi SI. HormMetab Res 2008; 40: 640-644 • Ostgren SJ. DiabetesObesMetab 2004; 6: 367-74 • DM and impairedglucosetolerance are associated with LVHwhichis a significantriskfactor for AF • Rutter MK. Circulation 2003; 107: 448-454 • Long-terminflammationmay be the mechmediating the link between DM and AF
CT Scan in an AFIB Patient With Ischemic Stroke in The Territory of the MCA AF increases of stroke risk 4-5 fold
Events Rate by StrokeRiskFactors, CHADS2 Score and Anticoagulation State in 11526 Adults With AF Go AS. JAMA. 2003; 290: 2685-2692
Human AF Substrate: Surgical Biopsies C Aimé-Sempé. J Am Coll Cardiol 1999;34:1577. SR Colagen (Mason’s tricrhomic) Elastic fibers (Orceine) AF
Neuroumoral Activation in AFIB HIGH ATRIAL PRESSURE OR VOLUME ATRIAL FIBROSIS ATRIAL REMODELING
Thiazolidinediones (Rosiglitazone)Agonists Of Peroxisome Proliferator Activated Receptor Gamma (PPAR-γ)Can Prevent New Onset AF In Pts With Non-insulinDependentDiabetes • TZDs have been proven to have - anti-inflammatoryand - anti-oxidant effects in addition to- anti-diabetic activity • 12,065 NIDDM pts from the “National Health Insurance Research Database” by the Taiwan National Health Research Institutes • 4137 ptswith TZD use were the study cohort and 7928 pts w/out TZD use were the comparison cohort -31% Chao TF, Chen SA, Int J Cardiol 2011; 156: 199-202
PPAR-γ Activator (Pioglitazone) as Upstream Therapy for Age-Related AF in Rats Xu D. J CardiovascElectrophysiol, 2012; 23: 209-217
Clinical Benefits Of TZDs On Atrial Fibrillation Prevention Home PD, et al. Rosiglitazoneevaluatedforcardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125–35 Dormandy, et al. Secondarypreventionofmacrovascularevents in patients with type 2 diabetes in the proACTIVE study (prospectivepioglitazoneclinical trial in macrovascularevents): a randomisedcontrolled trialLancet 2005;366:1279–89 DeFronzo, et al. Pioglitazonefordiabetespreventionin impaired glucose tolerance (ACT-NOW) N Engl J Med 2011;364:1104–15
AtrialFibrillation in DiabeticsDM is associated with an increased risk of subsequent AF but … • The population-attributable fraction of AF owing to DM is very low • Studies that had adjusted for multiple RFs reported a smaller effect • The risk associated with T2DM is mainly mediated by changes of other AF RF • The mech that may underpin the relation between DM and AF remains speculative • Long-terminflammationmay be the mechmediating the link between DM and AF • Rooms for furtherupstreamRxin AF • AF in diabeticspatientsexerts an elevatedthromboembolicrisk